ibalizumab   Click here for help

GtoPdb Ligand ID: 10208

Synonyms: Hu5A8 | ibalizumab-uiyk | TMB-355 | TMB355 | TNX-355 | Trogarzo®
Approved drug Immunopharmacology Ligand
ibalizumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Ibalizumab was originally reported as anti-CD4 monoclonal antibody 5A8 by Burkly et al. (1992 ) [1]. It is a non-immunosuppressive, humanised monoclonal antibody that acts as an HIV entry inhibitor [2,4]. Anti-HIV activity of TNX-355 (later to be assigned the INN ibalizumab) in patients was reported in 2004 [5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names Click here for help
INN number INN
8818 ibalizumab
Synonyms Click here for help
Hu5A8 | ibalizumab-uiyk | TMB-355 | TMB355 | TNX-355 | Trogarzo®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 241
Other databases
GtoPdb PubChem SID 381744890
Search PubMed clinical trials ibalizumab
Search PubMed titles ibalizumab
Search PubMed titles/abstracts ibalizumab